Fig. 1From: Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survivalStudy Flowchart shows patient enrollment, with the inclusion and exclusion criteriaBack to article page